Goldman Sachs’s Allena Pharmaceuticals ALNA Stock Holding History

Goldman Sachs’s Portfolio ALNA Stock Details ALNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-23,339	Closed	-$30K	–	6465
2020 Q4	$30K	Sell	23,339 -55,595	-70%	-$77.5K	﹤0.01%	5420
2020 Q3	$117K	Buy	78,934 +50,822	+181%	+$71.4K	﹤0.01%	5054
2020 Q2	$44K	Buy	+28,112	New	+$47.2K	﹤0.01%	5073
2020 Q1	–	Sell	-33,784	Closed	-$92K	–	5659
2019 Q4	$92K	Sell	33,784 -49,232	-59%	-$162K	﹤0.01%	5055
2019 Q3	$327K	Buy	83,016 +13,708	+20%	+$58.8K	﹤0.01%	4646
2019 Q2	$282K	Buy	69,308 +58,171	+522%	+$318K	﹤0.01%	4646
2019 Q1	$78K	Buy	+11,137	New	+$80.7K	﹤0.01%	4957
2018 Q4	–	Sell	-22,177	Closed	-$238K	–	5818
2018 Q3	$238K	Sell	22,177 -727	-3%	-$7.99K	﹤0.01%	4824
2018 Q2	$298K	Sell	22,904 -6,303	-22%	-$90.9K	﹤0.01%	4791
2018 Q1	$322K	Sell	29,207 -20,436	-41%	-$171K	﹤0.01%	4744
2017 Q4	$499K	Buy	+49,643	New	+$612K	﹤0.01%	4836

Other funds holding ALNA

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Goldman Sachs's ALNA Position: Q1 2021 in Review

Goldman Sachs sold out of Allena Pharmaceuticals (ALNA) in Q1 2021, closing a stake of 23,339 shares — an estimated $30K sold.

Goldman Sachs first reported a position in ALNA in Q4 2017 and held it in 11 quarters. The position peaked at $499K in Q4 2017. 30 funds tracked by Wall St. Rank hold ALNA as of Q1 2021.

Goldman Sachs reported no remaining Allena Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Goldman Sachs sold 23,339 Allena Pharmaceuticals shares in Q1 2021, an estimated $30K.
Goldman Sachs first reported a position in Allena Pharmaceuticals in Q4 2017 and held it in 11 quarters.
Goldman Sachs's Allena Pharmaceuticals position peaked at $499K in Q4 2017.
30 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q1 2021.

Based on Goldman Sachs's 13F filing for Q1 2021, filed 17 May 2021.